Similar articles for PMID: 31532537

Year	Number of Results
1980	1
2014	2
2015	4
2016	11
2017	15
2018	21
2019	22
2020	14
2021	12
2022	5
2023	1
2024	0

1

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors.

Ramondetta A, Ribero S, Conti L, Fava P, Marra E, Broganelli P, Caliendo V, Picciotto F, Guida M, Fierro MT, Quaglino P. Ramondetta A, et al. Acta Derm Venereol. 2020 Jan 7;100(1):adv00001. doi: 10.2340/00015555-3319. Acta Derm Venereol. 2020. PMID: 31532537 Free PMC article.

2

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. Review.

3

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.

Czarnecka AM, Teterycz P, Mariuk-Jarema A, Lugowska I, Rogala P, Dudzisz-Sledz M, Switaj T, Rutkowski P. Czarnecka AM, et al. Target Oncol. 2019 Dec;14(6):729-742. doi: 10.1007/s11523-019-00688-8. Target Oncol. 2019. PMID: 31754963

4

Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.

Consoli F, Manganoni AM, Grisanti S, Petrelli F, Venturini M, Rangoni G, Guarneri F, Incardona P, Vermi W, Calzavara Pinton PG, Berruti A. Consoli F, et al. PLoS One. 2019 Apr 2;14(4):e0214884. doi: 10.1371/journal.pone.0214884. eCollection 2019. PLoS One. 2019. PMID: 30939167 Free PMC article.

5

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.

Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard MA, Régis JM, Grob JJ. Gaudy-Marqueste C, et al. Eur J Cancer. 2017 Oct;84:44-54. doi: 10.1016/j.ejca.2017.07.017. Epub 2017 Aug 4. Eur J Cancer. 2017. PMID: 28783540

6

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R; German Dermatooncology Group (DeCOG/ADO). Hassel JC, et al. Cancer Med. 2018 Jan;7(1):95-104. doi: 10.1002/cam4.1267. Epub 2017 Dec 20. Cancer Med. 2018. PMID: 29266761 Free PMC article.

7

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A. Hu-Lieskovan S, et al. Sci Transl Med. 2015 Mar 18;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691. Sci Transl Med. 2015. PMID: 25787767 Free PMC article.

8

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Pires da Silva I, et al. J Immunother Cancer. 2022 Jul;10(7):e004610. doi: 10.1136/jitc-2022-004610. J Immunother Cancer. 2022. PMID: 35798536 Free PMC article.

9

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Br J Cancer. 2021 Mar;124(7):1222-1230. doi: 10.1038/s41416-020-01229-1. Epub 2021 Jan 26. Br J Cancer. 2021. PMID: 33495600 Free PMC article.

10

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, Weppler A, Angel C, Kee D, Bhave P, Lee B, Young RJ, Iravani A, Yeang HA, Vergara IA, Kok D, Drummond K, Neeson PJ, Sheppard KE, Papenfuss T, Solomon BJ, Sandhu S, McArthur GA. Lau PKH, et al. J Immunother Cancer. 2021 Oct;9(10):e002995. doi: 10.1136/jitc-2021-002995. J Immunother Cancer. 2021. PMID: 34625515 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

95 results

Results by year